

To: [REDACTED] [REDACTED] [REDACTED] @rivm.nl; [REDACTED] [REDACTED] [REDACTED] @rivm.nl; [REDACTED] [REDACTED] [REDACTED] @rivm.nl; [REDACTED]  
[REDACTED] [REDACTED] @rivm.nl  
Cc: [REDACTED] [REDACTED] [REDACTED] @astrazeneca.com]  
From: [REDACTED] [REDACTED] [REDACTED]  
Sent: Mon 3/22/2021 7:36:51 AM  
Subject: FYI - Covid-19 Vaccine AZ US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis  
Received: Mon 3/22/2021 7:36:59 AM

Beste allen,

Bijgaand de pers release van de high-level data van een interim analyse van de US fase III studie van on vaccin:

The data show that the vaccine demonstrated statistically significant **vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation**. This US Phase III trial included two doses administered at a 4 week interval.

- Vaccine efficacy was **consistent across ethnicity and age**. Notably, vaccine efficacy was **80% in participants aged 65 years and over**, who represented approximately 20% of participants.
- This interim safety and efficacy analysis was based on 32,449 participants across 88 trial centres in the US, Peru and Chile accruing 141 symptomatic cases of COVID-19. The vaccine was **well tolerated**, and the data safety monitoring board (DSMB) identified **no safety concerns** related to the vaccine.
- The DSMB also conducted a **specific review of thromboembolic events** across the US trial data and found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for cerebral venous sinus thrombosis (CVST) found no events in this trial.

Bij eventuele vragen hoor ik het graag!

Met vriendelijke groet,

[REDACTED]  
5.1.2e

---

**AstraZeneca BV**


Postbus 599, 2700 AN Zoetermeer

T: +31 [REDACTED] 5.1.2e F: +31 [REDACTED] 5.1.2e M: +31 [REDACTED] 5.1.2e  
[REDACTED] 5.1.2e [@astrazeneca.com](mailto:[REDACTED]@astrazeneca.com)

Please consider the environment before printing this e-mail

This e-mail is intended solely for the use of the addressee and is not meant for distribution or disclosure outside AstraZeneca. The information in this e-mail may be personal or confidential. Any views or opinions presented do not necessarily represent those of AstraZeneca. Should you receive this message by mistake, please notify the sender immediately and delete this e-mail from your system without opening the attachment.

[Click here to view online](#)



## AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis


---


**22 March 2021**

The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation.

*Read more* 

 [RSS Feed](#)

 [Follow us on Twitter](#)

 [Follow us on LinkedIn](#)

[Legal notice and Terms of Use](#)

[Privacy policy](#)

[Cookie policy](#)

[Site map](#)

[© AstraZeneca 2021](#)

For more information please visit [astrazeneca.com](https://www.astrazeneca.com).

If you would like to unsubscribe please [click here](#).